Boosted trees characterize distressing hot flashes after breast cancer treatment
Source check: Source checked. Not independent scientific confirmation.
Finding: LightGBM analysis of cross-sectional surveys from 360 early-breast-cancer patients associated reported hot-flash frequency and age with symptom-related distress. Nested internal validation gave AUC 0.731, and partial-dependence analysis suggested greater distress around seventeen or more hot flashes per week. This characterizes concurrent symptoms, not future toxicity or treatment efficacy. Recall bias, inconsistent survey-scale origins and predictors reflecting responses to existing symptoms limit interpretation.
Technology: LightGBM gradient-boosted decision trees; conditional partial dependence
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- Boosted trees learn nonlinear relationships among survey measurements and current reported symptom burden, with conditional partial dependence characterizing frequency/age associations.
- Test and result
- Survey-derived classification of current high versus low Hot Flush Night Sweats problem scores, with nested ten-fold outer/five-fold inner validation, Bayesian tuning and permutation-and-retraining importance.
- Limitation / still unknown
- Prospective symptom forecasts, independent validation and benefits of symptom screening or medication remain unestablished. Drug use and cancer-treatment changes may follow rather than precede severe symptoms; the symptom threshold is exploratory.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC9385785/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 21 Nov 2026. Review scope: Primary relevant outcome definition, predictor construction, LightGBM and nested-validation Methods, results and limitations. Supplementary Appendix C was not inspected. Exact primary identity/date and fresh primary PubMed correction/retraction relationships checked..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.